SignaBlok is discovering and developing innovative, first-in-class therapeutic and diagnostic agents for modulation and visualization of inflammatory immune response to benefit patients with a variety of unmet medical needs.

We believe that collaborations and partnerships are crucial to success. We are committed to matching our groundbreaking science, broad experience, skills and projects with the best professionals and companies in the field.

If you are interested in partnering with us, please  contact us through

To date, SignaBlok secured multiple high-profile partnerships and collaborations in our core therapeutic areas.

U.S. Department of Defense"